Sinco Pharma released an updated roster of its Board of Directors and committee assignments, effective 22 May 2026, outlining a seven-member Board and the leadership of four key governance committees.
The Board now comprises two Executive Directors—Chairman Mr. Huang Zhijian and Mr. Lei Shifeng—one Non-executive Director, Ms. Jing Huan, and four Independent Non-executive Directors (INEDs): Mr. Bai Zhizhong, Mr. Lau Ying Kit, Mr. Wang Qing, and Mr. Liu Wenfang. Mr. Bai Zhizhong also serves as Lead INED.
Committee leadership is distributed as follows: • Audit Committee: chaired by INED Mr. Lau Ying Kit, with members Mr. Wang Qing, Mr. Liu Wenfang, and Mr. Bai Zhizhong. • Remuneration Committee: chaired by INED Mr. Wang Qing, with members Mr. Lei Shifeng, Mr. Liu Wenfang, and Mr. Bai Zhizhong. • Nomination Committee: chaired by Executive Director Mr. Huang Zhijian, with members Mr. Lei Shifeng, Ms. Jing Huan, Mr. Liu Wenfang, and Mr. Bai Zhizhong. • Internal Control and Corporate Governance Committee: chaired by INED Mr. Lau Ying Kit, with members Mr. Huang Zhijian, Mr. Wang Qing, Mr. Liu Wenfang, and Mr. Bai Zhizhong.
The disclosure formalizes the company’s governance framework, delineating clear responsibilities across audit, remuneration, nomination, and internal control functions. Sinco Pharma states no other changes beyond the committee assignments.
Comments